Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Regulated upon activation, normal T cell expressed and secreted (RANTES) levels in the peripheral blood of patients with Alzheimer's disease

G. Vacinova, D. Vejražkova, R. Rusina, I. Holmerová, H. Vaňková, E. Jarolímová, J. Včelák, B. Bendlová, M. Vaňková,

. 2021 ; 16 (4) : 796-800. [pub] -

Jazyk angličtina Země Indie

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21001473

Alzheimer's disease (AD) is the most common type of dementia, but it is very difficult to diagnose with certainty, so many AD studies have attempted to find early and relevant diagnostic markers. Regulated upon activation, normal T cell expressed and secreted (RANTES, also known as C-C chemokine ligand) is a chemokine involved in the migration of T cells and other lymphoid cells. Changes in RANTES levels and its expression in blood or in cerebrospinal fluid have been reported in some neurodegenerative diseases, such as Parkinson's disease and multiple sclerosis, but also in metabolic diseases in which inflammation plays a role. The aim of this observational study was to assess RANTES levels in peripheral blood as clinical indicators of AD. Plasma levels of RANTES were investigated in 85 AD patients in a relatively early phase of AD (median 8.5 months after diagnosis; 39 men and 46 women; average age 75.7 years), and in 78 control subjects (24 men and 54 women; average age 66 years). We found much higher plasma levels of RANTES in AD patients compared to controls. A negative correlation of RANTES levels with age, disease duration, Fazekas scale score, and the medial temporal lobe atrophy (MTA) score (Scheltens's scale) was found in AD patients, i.e., the higher levels corresponded to earlier stages of the disease. Plasma RANTES levels were not correlated with cognitive scores. In AD patients, RANTES levels were positively correlated with the levels of pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-α, which is consistent with the well-known fact that AD is associated with inflammatory processes. RANTES levels were also positively correlated with insulin levels in AD patients, with insulin resistance (HOMA-R) and pancreatic beta cell function (HOMA-F). This study evaluated several clinical and metabolic factors that may affect plasma levels of RANTES, but these factors could not explain the increases in RANTES levels observed in AD patients. Plasma levels of RANTES appear to be an interesting peripheral marker for early stages of AD. The study was approved by the Ethics Committee of Institute of Endocrinology, Prague, Czech Republic on July 22, 2011.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21001473
003      
CZ-PrNML
005      
20210126092644.0
007      
ta
008      
210105s2021 ii f 000 0|eng||
009      
AR
024    7_
$a 10.4103/1673-5374.295340 $2 doi
035    __
$a (PubMed)33063745
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ii
100    1_
$a Vacinova, Gabriela $u Department of Molecular Endocrinology, Institute of Endocrinology; Department of Anthropology and Human Genetics, Faculty of Science, Charles University, Prague, Czech Republic.
245    10
$a Regulated upon activation, normal T cell expressed and secreted (RANTES) levels in the peripheral blood of patients with Alzheimer's disease. / $c G. Vacinova, D. Vejražkova, R. Rusina, I. Holmerová, H. Vaňková, E. Jarolímová, J. Včelák, B. Bendlová, M. Vaňková,
520    9_
$a Alzheimer's disease (AD) is the most common type of dementia, but it is very difficult to diagnose with certainty, so many AD studies have attempted to find early and relevant diagnostic markers. Regulated upon activation, normal T cell expressed and secreted (RANTES, also known as C-C chemokine ligand) is a chemokine involved in the migration of T cells and other lymphoid cells. Changes in RANTES levels and its expression in blood or in cerebrospinal fluid have been reported in some neurodegenerative diseases, such as Parkinson's disease and multiple sclerosis, but also in metabolic diseases in which inflammation plays a role. The aim of this observational study was to assess RANTES levels in peripheral blood as clinical indicators of AD. Plasma levels of RANTES were investigated in 85 AD patients in a relatively early phase of AD (median 8.5 months after diagnosis; 39 men and 46 women; average age 75.7 years), and in 78 control subjects (24 men and 54 women; average age 66 years). We found much higher plasma levels of RANTES in AD patients compared to controls. A negative correlation of RANTES levels with age, disease duration, Fazekas scale score, and the medial temporal lobe atrophy (MTA) score (Scheltens's scale) was found in AD patients, i.e., the higher levels corresponded to earlier stages of the disease. Plasma RANTES levels were not correlated with cognitive scores. In AD patients, RANTES levels were positively correlated with the levels of pro-inflammatory cytokines interleukin-6 and tumor necrosis factor-α, which is consistent with the well-known fact that AD is associated with inflammatory processes. RANTES levels were also positively correlated with insulin levels in AD patients, with insulin resistance (HOMA-R) and pancreatic beta cell function (HOMA-F). This study evaluated several clinical and metabolic factors that may affect plasma levels of RANTES, but these factors could not explain the increases in RANTES levels observed in AD patients. Plasma levels of RANTES appear to be an interesting peripheral marker for early stages of AD. The study was approved by the Ethics Committee of Institute of Endocrinology, Prague, Czech Republic on July 22, 2011.
655    _2
$a časopisecké články $7 D016428
700    1_
$a Vejražkova, Daniela $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic.
700    1_
$a Rusina, Robert $u Department of Neurology, Third Faculty of Medicine of Charles University and Thomayer Hospital Prague, Czech Republic.
700    1_
$a Holmerová, Iva $u II. Internal Medicine Clinic, Third Faculty of Medicine, Charles University, Prague; Faculty of Humanitites, Charles University Prague, Czech Republic.
700    1_
$a Vaňková, Hana $u II. Internal Medicine Clinic, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Jarolímová, Eva $u II. Internal Medicine Clinic, Third Faculty of Medicine, Charles University, Prague, Czech Republic.
700    1_
$a Včelák, Josef $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic.
700    1_
$a Bendlová, Běla $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic.
700    1_
$a Vaňková, Markéta $u Department of Molecular Endocrinology, Institute of Endocrinology, Prague, Czech Republic.
773    0_
$w MED00167287 $t Neural regeneration research $x 1673-5374 $g Roč. 16, č. 4 (2021), s. 796-800
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33063745 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210126092640 $b ABA008
999    __
$a ind $b bmc $g 1613896 $s 1121757
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 16 $c 4 $d 796-800 $e - $i 1673-5374 $m Neural regeneration research $n Nerual Regen. Res. $x MED00167287
LZP    __
$a Pubmed-20210105

Najít záznam

Citační ukazatele

Možnosti archivace